BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32285172)

  • 1. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
    Liu Q; Wu H; Li Y; Zhang R; Kleeff J; Zhang X; Cui M; Liu J; Li T; Gao J; Pan B; Wu W; Wang W; Zhou L; Guo J; Dai M; Zhang T; Liao Q; Lu Z; Zhao Y
    Cancer Immunol Immunother; 2020 Aug; 69(8):1477-1492. PubMed ID: 32285172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
    Li D; Schaub N; Guerin TM; Bapiro TE; Richards FM; Chen V; Talsania K; Kumar P; Gilbert DJ; Schlomer JJ; Kim SJ; Sorber R; Teper Y; Bautista W; Palena C; Ock CY; Jodrell DI; Pate N; Mehta M; Zhao Y; Kozlov S; Rudloff U
    Mol Cancer Ther; 2021 Oct; 20(10):1926-1940. PubMed ID: 34376576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
    Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
    Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
    Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
    Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.
    Liu Q; Li Y; Niu Z; Zong Y; Wang M; Yao L; Lu Z; Liao Q; Zhao Y
    J Exp Clin Cancer Res; 2016 Feb; 35():33. PubMed ID: 26879926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
    Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
    Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
    Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
    Sempere LF; Gunn JR; Korc M
    Cancer Biol Ther; 2011 Aug; 12(3):198-207. PubMed ID: 21613822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
    Liu C; Cheng H; Luo G; Lu Y; Jin K; Guo M; Ni Q; Yu X
    Int J Oncol; 2017 Aug; 51(2):686-694. PubMed ID: 28714519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
    Hermann PC; Trabulo SM; Sainz B; Balic A; Garcia E; Hahn SA; Vandana M; Sahoo SK; Tunici P; Bakker A; Hidalgo M; Heeschen C
    PLoS One; 2013; 8(6):e66371. PubMed ID: 23825539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
    Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
    Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells.
    Timaner M; Letko-Khait N; Kotsofruk R; Benguigui M; Beyar-Katz O; Rachman-Tzemah C; Raviv Z; Bronshtein T; Machluf M; Shaked Y
    Cancer Res; 2018 Mar; 78(5):1253-1265. PubMed ID: 29301792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.
    Cioffi M; Trabulo S; Hidalgo M; Costello E; Greenhalf W; Erkan M; Kleeff J; Sainz B; Heeschen C
    Clin Cancer Res; 2015 May; 21(10):2325-37. PubMed ID: 25717063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.